Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026
Advertisement
The Board of Partners of E. Merck KG appointed Kai Beckmann as future Chair of the Executive Board and CEO of Merck. He will take over this position on May 1, 2026, from Belén Garijo, who will continue to lead the company until the end of her tenure, ensuring a seamless transition. Kai Beckmann will become Deputy CEO effective immediately and continue in his role as CEO of Electronics until a successor is announced.
Belén Garijo will leave Merck after 15 years in the company of which she led six years as CEO of Healthcare and since 2021 as Chair of the Executive Board and CEO of Merck. Key milestones of her tenure included steering the company through the Covid-19 pandemic and increasing geopolitical volatility, driving sustainable growth – organically and through a string-of-pearls of targeted portfolio moves including SpringWorks and the divestiture of Surface Solutions, and building a skill-powered, high-performing organization. In her previous role, as CEO of the Healthcare business sector, she drove unprecedented business transformation, particularly in China, where she built a significant presence for the Healthcare business sector of Merck. Additionally, she also led the global resubmission and commercialization of the multiple sclerosis drug Mavenclad and executed three divestitures that streamlined the Healthcare portfolio and positioned the business for sustainable growth. Following the end of her tenure, Belén Garijo will remain actively involved in the healthcare ecosystem to continue serving the needs of patients, her area of expertise and passion.
“I would like to thank Belén Garijo for expertly steering Merck safely through tumultuous years of transformative change and returning the company to profitable growth. She has shaped the company’s evolution into a globally leading science and technology company while nurturing a High Impact Culture and making our teams future ready. Under her exceptional leadership, Merck strengthened its position across Life Science, Healthcare, and Electronics, driving innovation and delivering impact on millions of patients and customers worldwide. With an unwavering commitment to our values and vision, and a proven ability to navigate challenges with resilience, she has laid a robust foundation for Merck’s continued success,” said Johannes Baillou, Chairman of the Executive Board of E. Merck KG.
“In Kai Beckmann we have the perfect homegrown leader, taking over the Chair of the Executive Board of Merck with extensive understanding of our global businesses as well as patient and customer needs. Beckmann’s proven transformational expertise will be fundamental to deliver the next chapter of our company’s growth. And his passion and vision for technology will drive much-needed impact for patients, customers and society. The longstanding collaboration and trust between Belén Garijo and Kai Beckmann will ensure a seamless transition period and continuity in our corporate management,” said Johannes Baillou.
Kai Beckmann has served as a Member of the Executive Board of Merck since 2011 and assumed responsibility for the Performance Materials business sector in 2017. Under his leadership, the sector underwent a comprehensive transformation to become a pureplay Electronics business. Today, the business sector serves as a key ecosystem player enabling the global semiconductor industry. Prior to his current role, Kai Beckmann served as Chief Administration Officer on the Executive Board; his responsibilities encompassed a broad portfolio of functions including, among others, HR, IT, and Merck’s headquarters and largest site in Darmstadt. Since joining Merck in 1989, Kai Beckmann has held global roles of increasing responsibility, such as Managing Director of Merck in Singapore & Malaysia as well as Chief Information Officer.
Beyond Merck, Kai Beckmann is the Chairman of the Supervisory Board of Bundesdruckerei Gruppe and serves as Vice President of the Confederation of German Employers’ Associations (BDA). From 2017 to 2024, he led the German Federation of Chemical Employers' Associations (BAVC).
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Change of managing directors at 5-HT Chemistry & Health - Innovation partner for companies in the chemical, pharmaceutical, and healthcare industries under new management
Boehringer Ingelheim Pharma GmbH & Co. KG - Ingelheim am Rhein, Germany
Herz- und Diabeteszentrum Nordrhein-Westfalen (Universitätsklinik der Ruhr-Universität Bochum) - Bad Oeynhausen, Germany
Lead Discovery Center GmbH - Dortmund, Germany
Living heart muscle slices drive RNA research into heart failure - Researchers place living human heart tissue in a nutrient solution and use it to test new drugs and innovative approaches to combat heart failure
Empa - St. Gallen, Switzerland
What Do Spiders Have in Common with Batteries? - Spider silk inspires new class of functional synthetic polymers: Conducting protein-based material could be used in fuel cells, batteries or act as sensor
Sensors against superbugs - Dangerous increase in antimicrobial resistance: Detect resistant pathogens faster and start customized treatment in good time
Circular economy for plastics - Biotechnological solutions for degradation and recycling of plastics
Artificial intelligence is drastically changing the healthcare sector - Companies are engaging with AI and investing in it, but only 29 percent feel well prepared to use GenAI for competitive advantage
Malaria Parasites Move on Right-Handed Helices - Motion patterns help the transition between tissue compartments